David P Gusky Net Worth

The estimated Net Worth of David P Gusky is at least $57.4 millier dollars as of 14 December 2018. David Gusky owns over 617 units of Avadel Pharmaceuticals plc stock worth over $55,733 and over the last 8 years David sold AVDL stock worth over $1,654.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Gusky AVDL stock SEC Form 4 insiders trading

David has made over 1 trades of the Avadel Pharmaceuticals plc stock since 2018, according to the Form 4 filled with the SEC. Most recently David sold 617 units of AVDL stock worth $1,654 on 14 December 2018.

The largest trade David's ever made was selling 617 units of Avadel Pharmaceuticals plc stock on 14 December 2018 worth over $1,654. On average, David trades about 103 units every 0 days since 2016. As of 14 December 2018 David still owns at least 4,083 units of Avadel Pharmaceuticals plc stock.

You can see the complete history of David Gusky stock trades at the bottom of the page.

What's David Gusky's mailing address?

David's mailing address filed with the SEC is C/O FLAMEL TECHNOLOGIES S.A, 33 AVENUE DU DR. GEORGES LEVY, VENISSIEUX, I0, 69200.

Insiders trading at Avadel Pharmaceuticals plc

Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over $7,791,038 worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth $4,366,224 . The most active insiders traders include Healthcare Master Fund Ltd ..., Kevin Broadfin Capital, Llc... et Naseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of $381,436. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth $29,000.

What does Avadel Pharmaceuticals plc do?

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.

Complete history of David Gusky stock trades at Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc executives and stock owners

Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Gregory J. Divis Jr.,
  CEO & Director
• Dr. Jordan S. Dubow M.D.,
  Consultant
• Thomas S. McHugh,
  Sr. VP & CFO
• Angie Woods,
  VP of People & Culture
• Richard Kim,
  Chief Commercial Officer
• Dr. Jason M. Vaughn,
  Sr. VP of Technical Operations
• Steven G. Sullivan,
  VP of Sales & Marketing and Head of Commercial Operations
• Christian Kalita Pharm.D,
  Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
• Séverine Martin,
  Director of HR and Corp. Projects
• Mark W. Elrod,
  VP of Sales
• Gregory J. Davis,
  VP of Corp. and Bus. Devel.
• Phillandas T. Thompson,
  See Remarks
• Marcus W Elrod,
  See Remarks
• David Monteith,
  See Remarks
• Healthcare Master Fund Ltd ...,
  
• Craig R Stapleton,
  Director
• Guillaume Cerutti,
  Director
• Michael F Kanan,
  See Remarks
• Christophe Navarre,
  Director
• Francis Fildes,
  Director
• Stephen G. Sullivan,
  See Remarks
• Scott A. Macke,
  See Remarks
• David P Gusky,
  See Remarks
• Jason Vaughn,
  Sr. VP, Technical Operations
• Mark Anthony Mc Camish,
  Director
• Healthcare Master Fund Ltd ...,
  
• Peter J. Thornton,
  Director
• Naseem Amin,
  Director
• Gregory J. Davis,
  See Remarks
• Dhiren D'silva,
  See Remarks
• James Edeerfield Management...,
  
• Assche Benoit Van,
  Director
• Geoffrey Michael Glass,
  Director
• Linda Palczuk,
  Director
• Michael S Anderson,
  Chief Executive Officer
• Kevin Broadfin Capital, Llc...,
  
• Eric J Ende,
  Director
• Thomas S Mchugh,
  Chief Financial Officer
• Jordan Dubow,
  Chief Medical Officer
• Richard J Kim,
  Chief Commercial Officer
• Gregory J Divis,
  Chief Executive Officer
• Douglas J Williamson,
  Chief Medical Officer